News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|February 21, 2025

Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL

Author(s)Ryan Haumschild, PharmD, MS, MBA, CPEL, Matthew Davids, MD, MMSc

Panelists discuss how patient-reported outcomes and real-world evidence influence clinical decision-making when selecting Bruton tyrosine kinase (BTK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

Episodes in this series

EP. 1 Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP. 1 Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP. 2 Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP. 2 Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP. 3 Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP. 3 Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP. 4 Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP. 4 Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP. 5 Future Directions and Research Priorities in BTKi Treatment Approaches

EP. 5 Future Directions and Research Priorities in BTKi Treatment Approaches

EP. 6 Latest Trends and Innovations in CLL and MCL Treatment

EP. 6 Latest Trends and Innovations in CLL and MCL Treatment

EP. 7 CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP. 7 CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP. 8 Navigating CLL Treatment Choices

EP. 8 Navigating CLL Treatment Choices

EP. 9 Therapy Sequencing in CLL

EP. 9 Therapy Sequencing in CLL

EP. 10 MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP. 10 MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP. 11 MCL Therapy Selection and Sequencing

EP. 11 MCL Therapy Selection and Sequencing

EP. 12 Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL

EP. 12 Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL

EP. 13 Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL

EP. 13 Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL

EP. 14 Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL

EP. 14 Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL

EP. 15 Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences

EP. 15 Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences

EP. 16 Implementation of Shared Decision-Making in BTK Inhibitor Treatment

EP. 16 Implementation of Shared Decision-Making in BTK Inhibitor Treatment

EP. 17 Optimizing BTK Inhibitor Treatment: Managing Adverse Effects and Adherence

EP. 17 Optimizing BTK Inhibitor Treatment: Managing Adverse Effects and Adherence

EP. 18 Future Directions and Overcoming Challenges in BTK Inhibitor Therapy

EP. 18 Future Directions and Overcoming Challenges in BTK Inhibitor Therapy

EP. 19 Impact of Access Challenges on Patient Outcomes in CLL and MCL Care

EP. 19 Impact of Access Challenges on Patient Outcomes in CLL and MCL Care

EP. 20 Balancing Clinical Benefits and Costs of BTK Inhibitors

EP. 20 Balancing Clinical Benefits and Costs of BTK Inhibitors

EP. 21 Inflation Reduction Act: Impact on Health Care Systems’ Utilization of BTK Inhibitors

EP. 21 Inflation Reduction Act: Impact on Health Care Systems’ Utilization of BTK Inhibitors

EP. 22 Inflation Reduction Act: Impact on Affordability of BTK Inhibitors

EP. 22 Inflation Reduction Act: Impact on Affordability of BTK Inhibitors

EP. 23 Inflation Reduction Act: Impact on Clinical Pathways for BTK Inhibitors

EP. 23 Inflation Reduction Act: Impact on Clinical Pathways for BTK Inhibitors

EP. 24 Inflation Reduction Act: Clinical Challenges

EP. 24 Inflation Reduction Act: Clinical Challenges

EP. 25 Payer Policies and Access Strategies

EP. 25 Payer Policies and Access Strategies

EP. 26 Strategies for Managing Costs of Long-Term BTK Inhibitor Therapy

EP. 26 Strategies for Managing Costs of Long-Term BTK Inhibitor Therapy

EP. 27 The Future of BTK Inhibitor Therapies in CLL and MCL

EP. 27 The Future of BTK Inhibitor Therapies in CLL and MCL

How do patient-reported outcomes and real-world evidence influence your clinical decision-making process when selecting BTK inhibitor therapies for CLL and MCL?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Future Directions and Unmet Needs in HER2+ Breast Cancer Therapy

ByTiffany Traina, MD, FASCO,Mark Pegram, MD,Sherry Shen, MD,Jules Cohen, MD,Rochelle Horadam, RPh, BCOP

February 4th 2026

Additional Emerging HER2-Targeted Therapies in NSCLC

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Joshua K. Sabari, MD,Jingxiao Jin, MD,Fred Hirsch, MD, PhD

February 4th 2026

Opportunities for Positioning TKIs as First-Line Therapy in HER2-Mutant NSCLC

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Joshua K. Sabari, MD,Jingxiao Jin, MD,Fred Hirsch, MD, PhD

February 4th 2026

Addressing Care Coordination and Financial Toxicity in HER2+ Breast Cancer

ByTiffany Traina, MD, FASCO,Mark Pegram, MD,Sherry Shen, MD,Jules Cohen, MD,Rochelle Horadam, RPh, BCOP

February 4th 2026

5 experts are featured in this series

Safety Considerations and Practical Strategies for Using Bispecific Antibodies in Multiple Myeloma

ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP

February 3rd 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

5 Things to Know About the Oral GLP-1 Era

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text